Eli Lilly and Company $LLY Shares Sold by Pallas Capital Advisors LLC

Key Points

• Pallas Capital Advisors LLC reduced its stake in Eli Lilly and Company by 10.7% during the second quarter, selling 2,121 shares, and now holds 17,687 shares valued at approximately $13.79 million.
• Eli Lilly reported a quarterly earnings per share of $6.31, surpassing analyst estimates and achieving a revenue of $15.56 billion, a 37.6% increase year-over-year.
$1.50 quarterly dividend with a 0.8% yield, reflecting a dividend payout ratio of 39.22%.

Pallas Capital Advisors LLC decreased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 10.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,687 shares of the company's stock after selling 2,121 shares during the quarter. Pallas Capital Advisors LLC's holdings in Eli Lilly and Company were worth $13,787,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Hobbs Wealth Management LLC lifted its position in Eli Lilly and Company by 0.8% during the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock valued at $1,205,000 after purchasing an additional 12 shares during the period. Hixon Zuercher LLC boosted its stake in shares of Eli Lilly and Company by 0.7% during the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock worth $1,477,000 after acquiring an additional 12 shares during the last quarter. O Brien Wealth Partners LLC lifted its stake in shares of Eli Lilly and Company by 25.5% during the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after buying an additional 12 shares in the last quarter. Ascent Capital Management LLC lifted its stake in shares of Eli Lilly and Company by 2.5% during the 1st quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock valued at $409,000 after buying an additional 12 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners lifted its stake in shares of Eli Lilly and Company by 2.7% during the 1st quarter. Tennessee Valley Asset Management Partners now owns 493 shares of the company's stock valued at $407,000 after buying an additional 13 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Down 1.2%

Eli Lilly and Company stock traded down $9.41 during trading hours on Friday, hitting $753.52. The company had a trading volume of 7,319,147 shares, compared to its average volume of 4,106,311. The firm has a market cap of $713.18 billion, a P/E ratio of 49.25, a P/E/G ratio of 1.06 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $939.86. The company has a 50-day moving average price of $739.17 and a two-hundred day moving average price of $772.98.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same period in the previous year, the company earned $3.92 EPS. The firm's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were given a dividend of $1.50 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. Eli Lilly and Company's dividend payout ratio is presently 39.22%.

Insider Activity at Eli Lilly and Company

In other news, Director J Erik Fyrwald bought 1,565 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the transaction, the director directly owned 74,578 shares of the company's stock, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jamere Jackson bought 200 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The shares were purchased at an average cost of $639.56 per share, with a total value of $127,912.00. Following the transaction, the director directly owned 9,402 shares of the company's stock, valued at $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 4,514 shares of company stock valued at $2,894,841 over the last three months. Company insiders own 0.13% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on LLY shares. UBS Group reduced their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Berenberg Bank restated a "hold" rating and issued a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a report on Wednesday. Leerink Partners restated a "market perform" rating and issued a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 7th. JPMorgan Chase & Co. reduced their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a report on Tuesday. Finally, DZ Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $939.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.